The next generation of non-invasive prenatal screening.

Using a simple blood draw from the mother, Panorama™ provides >99% combined accuracy for trisomies 13, 18, and 21, fetal sex and triploidy.  A microdeletion panel (including 22q11.2 deletion syndrome) is also available to provide unparalleled scope and reliability among non-invasive prenatal screens.


Expecting Parents
Learn More

Healthcare Providers
Learn More


Not all prenatal screens are created equal.  Click here to compare Panorama™ to other testing options. 



Click here to read Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Screening in a High-Risk and Low-Risk Cohort by E. Pergament, et al. This blinded study demonstrates equivalent performance in low-risk cases compared to the overall cohort.

Click here to watch our webinar with Chief Medical Officer Dr. Susan Gross and genetic counselor Melissa Stosic discussing the results of the US Clinical Trials for Panorama and address the questions you may have about the Panorama test.